WHAT IS CLAIMED IS:

1. A compound of formula I:



wherein,

R^5, R^{1a} and R^1 independently are hydrogen, C_{1-6} alkyl, halo, C_{1-6} alkoxy, C_{3-10} cycloalkyl, C_{6-10} aryl, and trihalovinyl, said aryl optionally substituted with 1-3 groups of R^a;

R^2 is hydrogen, C_{1-6} alkyl, and C_{3-10} cycloalkyl; taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO_2, N, or NR^{2a} and optionally substituted by 1-3 Ra groups;

R^{2a} is hydrogen, and C_{1-6} alkyl;

R^3 and R^{3a} are independently hydrogen, halo, C_{1-6} alkyl, C_{3-10} cycloalkyl, and C_{6-10} aryl, said aryl and alkyl optionally substituted with 1-3 groups of R^a; or

R^3 and R^{3a} taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO_2, N, or NR^{2a} and optionally substituted by 1-3 R^a groups;

R^4 is hydrogen, halo, C_{1-6} alkyl, and trihaloalkyl;

R^a represents C_{1-6} alkoxy, C_{1-6} alkyl, CF_3, nitro, amino, cyano, C_{1-6} alkylamino, or halogen; and

n represents 1-3;

or a pharmaceutically acceptable salt, enantiomer, or diasteriomer thereof.

2. A compound according to claim 1 wherein R^{1a} and R^1 independently are hydrogen, tert-butyl, 1,2,2-trichlorovinyl, or phenyl .

3. A compound according to claim 1 wherein R^2 is hydrogen or C_{1-4} alkyl, and n is 1.

4. A compound according to claim 1 wherein R^{1a} and R^1 independently are hydrogen, tert-butyl, 1,2,2-trichlorovinyl, or phenyl; R^2 is hydrogen or C_{1-4} alkyl, and n is 1.

5. A compound according to claim 4 wherein R^{1a} and R^1 are tert-butyl, and R^2 is hydrogen.

6. A compound which is:
2-aminomethyl-5-tert-butyl-3-phenylphenol,
2-aminomethyl-5-tert-butyl-3-(4-methylphenyl)phenol,
3,5-di-tert-butyl-2-[(ethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[1-(ethylamino)ethyl]phenol,
3,5-di-tert-butyl-2-[(methylamino)methyl]phenol,
3,5-bis(trichlorovinyl)-2-[(ethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(propylamino)methyl]phenol,
2-[(ethylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(butylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(cyclohexylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(hexylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(octylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(2-hydroxyethylamino)methyl]phenol,
tert-butyl N-(2,4-di-tert-butyl-6-hydroxybenzyl)-beta-alaninate,
3,5-di-tert-butyl-2-[(2-dimethylaminoethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(3-phenylpropylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(2-phenylethylamino)methyl]phenol,

3,5-Di-*tert*-butyl-2-[1-(ethylamino)ethyl]phenol,
3,5-Di-*tert*-butyl-2-[(propylamino)methyl]phenol,
3,5-Di-*tert*-butyl-2-{[(pyrazin-2-ylmethyll)amino]methyl}phenol,
2-(aminomethyl)-3,5-di-*tert*-butylphenol hydrochloride,
2-Aminomethyl-5-*tert*-butylphenol hydrochloride,
or pharmaceutically acceptable salts thereof.

7. A composition comprising a compound of claim 1 and a pharmaceutically acceptable salt thereof.

8. A composition comprising a compound of claim 6 and a pharmaceutically acceptable salt thereof.

9. A method for the treatment of malaria which comprises administering to a patient in need of such treatment a compound of formula I:



wherein,

R^5, R^{1a} and R^1 independently are hydrogen, C_{1-6} alkyl, halo, C_{1-6} alkoxy, C_{3-10} cycloalkyl, C_{6-10} aryl, and trihalovinyl, said aryl optionally substituted with 1-3 groups of R^a;

R^2 is hydrogen, C_{1-6} alkyl, and C_{3-10} cycloalkyl; taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO_2, N, or NR2a and optionally substituted by 1-3 Ra groups;

R^{2a} is hydrogen, and C_{1-6} alkyl;